Selective KCNQ Potassium Channel Modulators for Reduced Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current KCNQ openers, such as flupirtine and retigabine, used for treating conditions like pain, epilepsy, and anxiety, suffer from adverse effects like asthenia, ataxia, insomnia, and sedation, necessitating the development of compounds that selectively activate specific KCNQ subtypes to reduce side effects.
Innovation Solution
Development of compounds of formula (I) that modulate KCNQ potassium channels, specifically activating certain subtypes to treat pain and other disorders while minimizing adverse effects, including pharmaceutical compositions for administering these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current KCNQ openers (flupirtine and retigabine) are used to treat pain, epilepsy, and anxiety, then therapeutic efficacy is achieved, but adverse effects (asthenia, ataxia, insomnia, sedation) occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific substituent patterns (R1, R2, R3, R4, R5 groups) that confer selective affinity for particular KCNQ subtypes. This selectivity ensures the drug acts on specific target subtypes rather than all KCNQ channels uniformly, thereby achieving therapeutic efficacy while minimizing off-target adverse effects associated with non-selective activation
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical structure parameters (substituent types, positions, and configurations on the pyrimidine core) to optimize the balance between therapeutic efficacy and side effect profile. By adjusting these molecular parameters, the invention achieves compounds with improved selectivity and reduced adverse effects compared to parent compounds
2Object-generated harmful factors
If KCNQ openers are developed to selectively activate specific KCNQ subtypes, then side effects are reduced, but compound design complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular design into distinct modular components: a core pyrimidine structure with defined substituent positions (R1-R5). Each substituent position can be independently optimized for specific KCNQ subtype selectivity, allowing systematic development of selective agonists while maintaining a manageable structural framework that reduces overall design complexity
Solution Approach 2:
The patent employs universality by creating a multi-functional pyrimidine core structure that can accommodate various substituent combinations to target different KCNQ subtypes. This universal scaffold approach allows a single base structure to serve multiple therapeutic purposes by simply changing substituents, thereby reducing the need for entirely new molecular designs for each subtype
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively treat conditions like neuropathic pain, epilepsy, and anxiety with reduced side effects by selectively activating KCNQ channels, providing therapeutic benefits with improved safety profiles.
Implementation Method 1
Potassium channels are membrane-bound proteins responsible for regulating the flow of potassium ions through a cell membrane
Implementation Method 2
Activation of KCNQ channels by KCNQ openers causes an outflow of potassium ions from the cell, reducing the membrane potential (i.e., hyperpolarization), and thereby decreasing cellular excitability
Data Source
AI summary
Disclosed herein are KCNQ potassium channels modulators of formula (I)wherein R1, R2, R3, R4, and R5 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.